Last reviewed · How we verify
Reference0912
Reference0912 is a drug that targets the PD-1 receptor.
Reference0912 is a drug that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | Reference0912 |
|---|---|
| Sponsor | Sun Pharma Advanced Research Company Limited |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the PD-1 receptor, preventing its interaction with its ligands and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reference0912 CI brief — competitive landscape report
- Reference0912 updates RSS · CI watch RSS
- Sun Pharma Advanced Research Company Limited portfolio CI